Details of the Drug
General Information of Drug (ID: DMA2CZL)
| Drug Name |
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
rDADAE (11); CHEMBL229441; BDBM21127; single bond H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; reduced bond-c[2-D-allylglycine, 5-D-allylglycine]enkephalin; (5S,8R,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradecane-8-carboxylic acid
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 553.6 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -1.1 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 7 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 7 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||


